Bridgeway Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Bridgeway Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-28,900	Closed	-$190K	–	1383
2020 Q3	$190K	Sell	28,900 -280	-1%	-$1.9K	﹤0.01%	1183
2020 Q2	$217K	Buy	+29,180	New	+$199K	﹤0.01%	1133
2019 Q4	–	Sell	-7,450	Closed	-$78K	–	1406
2019 Q3	$78K	Hold	7,450	–	–	﹤0.01%	1257
2019 Q2	$127K	Sell	7,450 -5,000	-40%	-$135K	﹤0.01%	1227
2019 Q1	$420K	Hold	12,450	–	–	0.01%	1075
2018 Q4	$364K	Sell	12,450 -2,500	-17%	-$111K	﹤0.01%	1089
2018 Q3	$921K	Buy	14,950 +10,000	+202%	+$677K	0.01%	913
2018 Q2	$365K	Hold	4,950	–	–	﹤0.01%	1213
2018 Q1	$325K	Buy	+4,950	New	+$374K	﹤0.01%	1187

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's BLCM Position: Q4 2020 in Review

Bridgeway Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2020, closing a stake of 28,900 shares — an estimated $190K sold.

Bridgeway Capital Management first reported a position in BLCM in Q1 2018 and held it in 9 quarters. The position peaked at $921K in Q3 2018. 34 funds tracked by Wall St. Rank hold BLCM as of Q4 2020.

Bridgeway Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Bridgeway Capital Management sold 28,900 Bellicum Pharmaceuticals, Inc. shares in Q4 2020, an estimated $190K.
Bridgeway Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 9 quarters.
Bridgeway Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $921K in Q3 2018.
34 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2020.

Based on Bridgeway Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.